1XT Stock Overview
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Xintela AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.015 |
| 52 Week High | kr0.033 |
| 52 Week Low | kr0.007 |
| Beta | 1.64 |
| 1 Month Change | -15.56% |
| 3 Month Change | 7.04% |
| 1 Year Change | -9.52% |
| 3 Year Change | -94.66% |
| 5 Year Change | -97.29% |
| Change since IPO | -94.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1XT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 40.7% | 0.8% | 1.2% |
| 1Y | -9.5% | -24.4% | 2.0% |
Return vs Industry: 1XT exceeded the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 1XT underperformed the German Market which returned 2% over the past year.
Price Volatility
| 1XT volatility | |
|---|---|
| 1XT Average Weekly Movement | 53.4% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1XT's share price has been volatile over the past 3 months.
Volatility Over Time: 1XT's weekly volatility (53%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 21 | Evy Lundgren-Åkerlund | www.xintela.se |
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company develops products based on XINMARK, a patented technology platform; XSTEM, a stem cell platform for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; EQSTEM for the joint disease treatment in horses; CANISTEM for stem cell treatment in dogs; and XACT, an analytical test for cartilage cells. It is also involved in the development of TARG9 and TARG10, therapeutic antibodies targeting integrin aiopi for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.
Xintela AB (publ) Fundamentals Summary
| 1XT fundamental statistics | |
|---|---|
| Market cap | €13.11m |
| Earnings (TTM) | -€4.62m |
| Revenue (TTM) | €6.66k |
1,970x
P/S Ratio-2.8x
P/E RatioIs 1XT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1XT income statement (TTM) | |
|---|---|
| Revenue | kr78.00k |
| Cost of Revenue | kr0 |
| Gross Profit | kr78.00k |
| Other Expenses | kr54.16m |
| Earnings | -kr54.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 24, 2024
| Earnings per share (EPS) | -0.095 |
| Gross Margin | 100.00% |
| Net Profit Margin | -69,337.18% |
| Debt/Equity Ratio | 0% |
How did 1XT perform over the long term?
See historical performance and comparison